The next generation of gene therapy requires vectors that combine efficient gene delivery with improved safety and long-term therapeutic performance. NIMVEC’s proprietary replication-defective SV40 platform harnesses the natural properties of SV40 to escape the immune system’s surveillance while enabling sustained transgene expression and the potential for repeat dosing. By overcoming key limitations of conventional viral vectors, our technology opens new opportunities for gene replacement, immune tolerance induction, and the treatment of complex diseases requiring durable therapeutic outcomes.
